Opdivo Approval History
Opdivo (nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody for the treatment of advanced melanoma, advanced non-small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, advanced squamous cell carcinoma of the head and neck, urothelial carcinoma, MSI-H or dMMR metastatic colorectal cancer, and hepatocellular carcinoma.
Development History and FDA Approval Process for Opdivo
| Date | Article |
|---|
| Apr 16, 2018 |  FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) Combination as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma |
| Mar 6, 2018 | Bristol-Myers Squibb’s Opdivo (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing |
| Dec 20, 2017 | Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease |
| Sep 22, 2017 | Bristol-Myers Squibb’s Opdivo (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib |
| Aug 1, 2017 | Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Progressed Following Treatment |
| Feb 2, 2017 | Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma |
| Nov 10, 2016 | Bristol-Myers Squibb’s Opdivo (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer |
| May 17, 2016 | Opdivo (nivolumab) FDA Approved for the Treatment of Hodgkin Lymphoma |
| Jan 23, 2016 | Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status |
| Nov 23, 2015 | FDA Approves Opdivo to Treat Metastatic Renal Cell Carcinoma |
| Oct 9, 2015 | FDA Expands Approved Use of Opdivo (nivolumab) in Advanced Lung Cancer |
| Oct 1, 2015 | BMS Receives FDA Approval for Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Melanoma |
| Mar 4, 2015 | FDA Expands Approved use of Opdivo (nivolumab) to Treat Lung Cancer |
| Dec 22, 2014 | FDA Approves Opdivo (nivolumab) for Advanced Melanoma |
| Dec 6, 2014 | Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma |
| Nov 16, 2014 | Study Comparing Opdivo (nivolumab) to Chemotherapy Demonstrates Survival Benefit |
| Oct 30, 2014 | Phase 2 Objective Response Rate and Survival Data for Opdivo (nivolumab) in NSCLC to be Presented |
| Oct 6, 2014 | BMS Announces Collaboration to Evaluate Opdivo (nivolumab) in Combination to Treat Non-Small Cell Lung Cancer |
| Sep 26, 2014 | Bristol-Myers Squibb Announces Multiple Regulatory Milestones for Opdivo (nivolumab) |
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.
